Skip to main navigation Skip to search Skip to main content

NCCN Guidelines ® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines

  • Al B. Benson
  • , Alan P. Venook
  • , Mahmoud M. Al-Hawary
  • , Lynette Cederquist
  • , Yi Jen Chen
  • , Kristen K. Ciombor
  • , Stacey Cohen
  • , Harry S. Cooper
  • , Dustin Deming
  • , Paul F. Engstrom
  • , Ignacio Garrido-Laguna
  • , Jean L. Grem
  • , Axel Grothey
  • , Howard S. Hochster
  • , Sarah Hoffe
  • , Steven Hunt
  • , Ahmed Kamel
  • , Natalie Kirilcuk
  • , Smitha Krishnamurthi
  • , Wells A. Messersmith
  • Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, Deborah A. Freedman-Cass
  • Northwestern University
  • University of California at San Francisco
  • University of Michigan, Ann Arbor
  • University of California at San Diego
  • City of Hope National Medical Center
  • Vanderbilt University
  • Seattle Cancer Care Alliance
  • University of Wisconsin-Madison
  • Fox Chase Cancer Center
  • University of Utah
  • University of Nebraska Medical Center
  • Mayo Clinic
  • Yale University
  • University of South Florida
  • Washington University St. Louis
  • University of Alabama at Birmingham
  • Stanford University
  • Case Western Reserve University
  • University of Colorado Cancer Center
  • Dana-Farber/Brigham and Women's Cancer Center
  • Ohio State University
  • Roswell Park Comprehensive Cancer Center
  • Memorial Sloan-Kettering Cancer Center
  • University of Tennessee Health Science Center
  • University of Texas MD Anderson Cancer Center
  • Johns Hopkins University
  • Duke University
  • National Comprehensive Cancer Network

Research output: Contribution to journalComment/debate

797 Scopus citations

Abstract

The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation-positive metastatic colorectal cancer with regimens containing vemurafenib.

Original languageEnglish
Pages (from-to)359-369
Number of pages11
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume16
Issue number4
DOIs
StatePublished - Apr 1 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Colonic Neoplasms/diagnosis
  • Humans

Fingerprint

Dive into the research topics of 'NCCN Guidelines ® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines'. Together they form a unique fingerprint.

Cite this